Deoxynyboquinones as NQO1-Activated Cancer Therapeutics

Accounts of Chemical Research

Volumn 48, Issue 10, 2015, Pages 2715-2723

  Parkinson, Elizabeth I ^a   Hergenrother, Paul J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA-LAPACHONE; DEOXYNYBOQUINONE; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTINEOPLASTIC AGENTS; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; QUINONES; REACTIVE OXYGEN SPECIES;

EID: 84945916823     PISSN: 00014842     EISSN: 15204898     Source Type: Journal    
DOI: 10.1021/acs.accounts.5b00365     Document Type: Article

References (75)

1. Pavet, V.; Portal, M. M.; Moulin, J. C.; Herbrecht, R.; Gronemeyer, H. Towards novel paradigms for cancer therapy Oncogene 2011, 30, 1-20 10.1038/onc.2010.460
2. Siegel, D.; Yan, C.; Ross, D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones Biochem. Pharmacol. 2012, 83, 1033-40 10.1016/j.bcp.2011.12.017
3. Schlager, J. J.; Powis, G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol Int. J. Cancer 1990, 45, 403-9 10.1002/ijc.2910450304
4. Malkinson, A. M.; Siegel, D.; Forrest, G. L.; Gazdar, A. F.; Oie, H. K.; Chan, D. C.; Bunn, P. A.; Mabry, M.; Dykes, D. J.; Harrison, S. D.; Ross, D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl Cancer Res. 1992, 52, 4752-7
5. Smitskamp-Wilms, E.; Giaccone, G.; Pinedo, H. M.; van der Laan, B. F.; Peters, G. J. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br. J. Cancer 1995, 72, 917-21 10.1038/bjc.1995.433
6. Marin, A.; Lopez de Cerain, A.; Hamilton, E.; Lewis, A. D.; Martinez-Penuela, J. M.; Idoate, M. A.; Bello, J. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours Br. J. Cancer 1997, 76, 923-9 10.1038/bjc.1997.485
7. Siegel, D.; Ross, D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues Free Radical Biol. Med. 2000, 29, 246-53 10.1016/S0891-5849(00)00310-5
8. Kolesar, J. M.; Pritchard, S. C.; Kerr, K. M.; Kim, K.; Nicolson, M. C.; McLeod, H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue Int. J. Oncol. 2002, 21, 1119-24 10.3892/ijo.21.5.1119
9. Bey, E. A.; Bentle, M. S.; Reinicke, K. E.; Dong, Y.; Yang, C. R.; Girard, L.; Minna, J. D.; Bornmann, W. G.; Gao, J.; Boothman, D. A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 11832-7 10.1073/pnas.0702176104
10. Li, Z.; Zhang, Y.; Jin, T.; Men, J.; Lin, Z.; Qi, P.; Piao, Y.; Yan, G. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers BMC Cancer 2015, 15, 207 10.1186/s12885-015-1227-8
11. Yang, Y.; Zhang, Y.; Wu, Q.; Cui, X.; Lin, Z.; Liu, S.; Chen, L. Clinical implications of high NQO1 expression in breast cancers J. Exp. Clin. Cancer Res. 2014, 33, 14 10.1186/1756-9966-33-14
12. Mikami, K.; Naito, M.; Ishiguro, T.; Yano, H.; Tomida, A.; Yamada, T.; Tanaka, N.; Shirakusa, T.; Tsuruo, T. Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase Jpn. J. Cancer Res. 1998, 89, 910-5 10.1111/j.1349-7006.1998.tb00648.x
13. Ji, L.; Wei, Y.; Jiang, T.; Wang, S. Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival Int. J. Clin. Exp. Pathol. 2014, 7, 1124-31
14. Logsdon, C. D.; Simeone, D. M.; Binkley, C.; Arumugam, T.; Greenson, J. K.; Giordano, T. J.; Misek, D. E.; Kuick, R.; Hanash, S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer Cancer Res. 2003, 63, 2649-57
15. Lewis, A. M.; Ough, M.; Hinkhouse, M. M.; Tsao, M. S.; Oberley, L. W.; Cullen, J. J. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer Mol. Carcinog. 2005, 43, 215-24 10.1002/mc.20107
16. Lyn-Cook, B. D.; Yan-Sanders, Y.; Moore, S.; Taylor, S.; Word, B.; Hammons, G. J. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas Cell Biol. Toxicol. 2006, 22, 73-80 10.1007/s10565-006-0156-3
17. Awadallah, N. S.; Dehn, D.; Shah, R. J.; Russell Nash, S.; Chen, Y. K.; Ross, D.; Bentz, J. S.; Shroyer, K. R. NQO1 expression in pancreatic cancer and its potential use as a biomarker Appl. Immunohistochem Mol. Morphol 2008, 16, 24-31 10.1097/PAI.0b013e31802e91d0
18. Cui, X.; Li, L.; Yan, G.; Meng, K.; Lin, Z.; Nan, Y.; Jin, G.; Li, C. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma BMC Cancer 2015, 15, 244 10.1186/s12885-015-1271-4
19. Lin, L.; Qin, Y.; Jin, T.; Liu, S.; Zhang, S.; Shen, X.; Lin, Z. Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma Exp. Mol. Pathol. 2014, 96, 200-5 10.1016/j.yexmp.2013.12.008
20. Ma, Y.; Kong, J.; Yan, G.; Ren, X.; Jin, D.; Jin, T.; Lin, L.; Lin, Z. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix BMC Cancer 2014, 14, 414 10.1186/1471-2407-14-414
21. Cheng, Y.; Li, J.; Martinka, M.; Li, G. The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas Oncol. Rep. 2010, 23, 973-9 10.3892/or-00000722
22. Leinonen, H. M.; Kansanen, E.; Polonen, P.; Heinaniemi, M.; Levonen, A. L. Role of the Keap1-Nrf2 pathway in cancer Adv. Cancer Res. 2014, 122, 281-320 10.1016/B978-0-12-420117-0.00008-6
23. Hayes, J. D.; McMahon, M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer Trends Biochem. Sci. 2009, 34, 176-88 10.1016/j.tibs.2008.12.008
24. Solis, L. M.; Behrens, C.; Dong, W.; Suraokar, M.; Ozburn, N. C.; Moran, C. A.; Corvalan, A. H.; Biswal, S.; Swisher, S. G.; Bekele, B. N.; Minna, J. D.; Stewart, D. J.; Wistuba, II Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features Clin. Cancer Res. 2010, 16, 3743-53 10.1158/1078-0432.CCR-09-3352
25. CancerGenomeAtlasNetwork Comprehensive genomic characterization of squamous cell lung cancers Nature 2012, 489, 519-525 10.1038/nature11404
26. Onodera, Y.; Motohashi, H.; Takagi, K.; Miki, Y.; Shibahara, Y.; Watanabe, M.; Ishida, T.; Hirakawa, H.; Sasano, H.; Yamamoto, M.; Suzuki, T. NRF2 immunolocalization in human breast cancer patients as a prognostic factor Endocr.-Relat. Cancer 2014, 21, 241-52 10.1530/ERC-13-0234
27. Konstantinopoulos, P. A.; Spentzos, D.; Fountzilas, E.; Francoeur, N.; Sanisetty, S.; Grammatikos, A. P.; Hecht, J. L.; Cannistra, S. A. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer Cancer Res. 2011, 71, 5081-9 10.1158/0008-5472.CAN-10-4668
28. Schulze, K.; Imbeaud, S.; Letouze, E.; Alexandrov, L. B.; Calderaro, J.; Rebouissou, S.; Couchy, G.; Meiller, C.; Shinde, J.; Soysouvanh, F.; Calatayud, A. L.; Pinyol, R.; Pelletier, L.; Balabaud, C.; Laurent, A.; Blanc, J. F.; Mazzaferro, V.; Calvo, F.; Villanueva, A.; Nault, J. C.; Bioulac-Sage, P.; Stratton, M. R.; Llovet, J. M.; Zucman-Rossi, J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets Nat. Genet. 2015, 47, 505-11 10.1038/ng.3252
29. Kovac, M.; Navas, C.; Horswell, S.; Salm, M.; Bardella, C.; Rowan, A.; Stares, M.; Castro-Giner, F.; Fisher, R.; de Bruin, E. C.; Kovacova, M.; Gorman, M.; Makino, S.; Williams, J.; Jaeger, E.; Jones, A.; Howarth, K.; Larkin, J.; Pickering, L.; Gore, M.; Nicol, D. L.; Hazell, S.; Stamp, G.; O'Brien, T.; Challacombe, B.; Matthews, N.; Phillimore, B.; Begum, S.; Rabinowitz, A.; Varela, I.; Chandra, A.; Horsfield, C.; Polson, A.; Tran, M.; Bhatt, R.; Terracciano, L.; Eppenberger-Castori, S.; Protheroe, A.; Maher, E.; El Bahrawy, M.; Fleming, S.; Ratcliffe, P.; Heinimann, K.; Swanton, C.; Tomlinson, I. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution Nat. Commun. 2015, 6, 6336 10.1038/ncomms7336
30. Cullen, J. J.; Hinkhouse, M. M.; Grady, M.; Gaut, A. W.; Liu, J.; Zhang, Y. P.; Weydert, C. J.; Domann, F. E.; Oberley, L. W. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism Cancer Res. 2003, 63, 5513-20
31. Winski, S. L.; Faig, M.; Bianchet, M. A.; Siegel, D.; Swann, E.; Fung, K.; Duncan, M. W.; Moody, C. J.; Amzel, L. M.; Ross, D. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches Biochemistry 2001, 40, 15135-42 10.1021/bi011324i
32. Reigan, P.; Colucci, M. A.; Siegel, D.; Chilloux, A.; Moody, C. J.; Ross, D. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells Biochemistry 2007, 46, 5941-50 10.1021/bi700008y
33. Danson, S.; Ward, T. H.; Butler, J.; Ranson, M. DT-diaphorase: a target for new anticancer drugs Cancer Treat. Rev. 2004, 30, 437-49 10.1016/j.ctrv.2004.01.002
34. Lou, Y.; Li, R.; Xiong, L.; Gu, A.; Shi, C.; Chu, T.; Zhang, X.; Gu, P.; Zhong, H.; Wen, S.; Han, B. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis Tumor Biol. 2013, 34, 3967-79 10.1007/s13277-013-0985-7
35. Peng, Q.; Lu, Y.; Lao, X.; Chen, Z.; Li, R.; Sui, J.; Qin, X.; Li, S. The NQO1 Pro187Ser. polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis Diagn. Pathol. 2014, 9, 100 10.1186/1746-1596-9-100
36. Kelsey, K. T.; Ross, D.; Traver, R. D.; Christiani, D. C.; Zuo, Z. F.; Spitz, M. R.; Wang, M.; Xu, X.; Lee, B. K.; Schwartz, B. S.; Wiencke, J. K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy Br. J. Cancer 1997, 76, 852-4 10.1038/bjc.1997.474
37. Dinkova-Kostova, A. T.; Talalay, P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector Arch. Biochem. Biophys. 2010, 501, 116-23 10.1016/j.abb.2010.03.019
38. Ross, D.; Kepa, J. K.; Winski, S. L.; Beall, H. D.; Anwar, A.; Siegel, D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms Chem.-Biol. Interact. 2000, 129, 77-97 10.1016/S0009-2797(00)00199-X
39. Deller, S.; Macheroux, P.; Sollner, S. Flavin-dependent quinone reductases Cell. Mol. Life Sci. 2008, 65, 141-60 10.1007/s00018-007-7300-y
40. Siegel, D.; Beall, H.; Senekowitsch, C.; Kasai, M.; Arai, H.; Gibson, N. W.; Ross, D. Bioreductive activation of mitomycin C by DT-diaphorase Biochemistry 1992, 31, 7879-85 10.1021/bi00149a019
41. Fitzsimmons, S. A.; Workman, P.; Grever, M.; Paull, K.; Camalier, R.; Lewis, A. D. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9 J. Natl. Cancer Inst 1996, 88, 259-69 10.1093/jnci/88.5.259
42. Nemeikaite-Ceniene, A.; Sarlauskas, J.; Anusevicius, Z.; Nivinskas, H.; Cenas, N. Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress Arch. Biochem. Biophys. 2003, 416, 110-8 10.1016/S0003-9861(03)00281-9
43. Ross, D.; Beall, H. D.; Siegel, D.; Traver, R. D.; Gustafson, D. L. Enzymology of bioreductive drug activation Br. J. Cancer, Suppl. 1996, 27, S1-8
44. Colucci, M. A.; Moody, C. J.; Couch, G. D. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential Org. Biomol. Chem. 2008, 6, 637-56 10.1039/B715270A
45. Beall, H. D.; Winski, S. I. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development Front. Biosci., Landmark Ed. 2000, 5, D639-48 10.2741/Beall
46. Parkinson, E. I.; Bair, J. S.; Cismesia, M.; Hergenrother, P. J. Efficient NQO1 Substrates are Potent and Selective Anticancer Agents ACS Chem. Biol. 2013, 8, 2173-83 10.1021/cb4005832
47. Guo, W.; Reigan, P.; Siegel, D.; Zirrolli, J.; Gustafson, D.; Ross, D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition Cancer Res. 2005, 65, 10006-15 10.1158/0008-5472.CAN-05-2029
48. Gaspar, N.; Sharp, S. Y.; Pacey, S.; Jones, C.; Walton, M.; Vassal, G.; Eccles, S.; Pearson, A.; Workman, P. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells Cancer Res. 2009, 69, 1966-75 10.1158/0008-5472.CAN-08-3131
49. Douglas, M.; Lim, A. R.; Porter, J. R.; West, K.; Pink, M. M.; Ge, J.; Wylie, A. A.; Tibbits, T. T.; Biggs, K.; Curtis, M.; Palombella, V. J.; Adams, J.; Fritz, C. C.; Normant, E. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo Mol. Cancer Ther. 2009, 8, 3369-78 10.1158/1535-7163.MCT-09-0568
50. Huang, X.; Dong, Y.; Bey, E. A.; Kilgore, J. A.; Bair, J. S.; Li, L. S.; Patel, M.; Parkinson, E. I.; Wang, Y.; Williams, N. S.; Gao, J.; Hergenrother, P. J.; Boothman, D. A. An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis Cancer Res. 2012, 72, 3038-47 10.1158/0008-5472.CAN-11-3135
51. Beall, H. D.; Mulcahy, R. T.; Siegel, D.; Traver, R. D.; Gibson, N. W.; Ross, D. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases Cancer Res. 1994, 54, 3196-201
52. Yee, S. B.; Pritsos, C. A. Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase Arch. Biochem. Biophys. 1997, 347, 235-41 10.1006/abbi.1997.0340
53. Smith, G. M.; Gordon, J. A.; Sewell, I. A.; Ellis, H. A trial of streptonigrin in the treatment of advanced malignant disease Br. J. Cancer 1967, 21, 295-301 10.1038/bjc.1967.32
54. Pink, J. J.; Planchon, S. M.; Tagliarino, C.; Varnes, M. E.; Siegel, D.; Boothman, D. A. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity J. Biol. Chem. 2000, 275, 5416-24 10.1074/jbc.275.8.5416
55. Bey, E. A.; Bentle, M. S.; Reinicke, K. E.; Dong, Y.; Yang, C. R.; Girard, L.; Minna, J. D.; Bornmann, W. G.; Gao, J.; Boothman, D. A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 11832-7 10.1073/pnas.0702176104
56. Planchon, S. M.; Pink, J. J.; Tagliarino, C.; Bornmann, W. G.; Varnes, M. E.; Boothman, D. A. beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3 Exp. Cell Res. 2001, 267, 95-106 10.1006/excr.2001.5234
57. Ough, M.; Lewis, A.; Bey, E. A.; Gao, J.; Ritchie, J. M.; Bornmann, W.; Boothman, D. A.; Oberley, L. W.; Cullen, J. J. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1 Cancer Biol. Ther. 2005, 4, 95-102 10.4161/cbt.4.1.1382
58. Li, L. S.; Bey, E. A.; Dong, Y.; Meng, J.; Patra, B.; Yan, J.; Xie, X. J.; Brekken, R. A.; Barnett, C. C.; Bornmann, W. G.; Gao, J.; Boothman, D. A. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy Clin. Cancer Res. 2011, 17, 275-85 10.1158/1078-0432.CCR-10-1983
59. Park, E. J.; Min, K. J.; Lee, T. J.; Yoo, Y. H.; Kim, Y. S.; Kwon, T. K. beta-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells Cell Death Dis. 2014, 5, e1230 10.1038/cddis.2014.202
60. Bey, E. A.; Reinicke, K. E.; Srougi, M. C.; Varnes, M.; Anderson, V. E.; Pink, J. J.; Li, L. S.; Patel, M.; Cao, L.; Moore, Z.; Rommel, A.; Boatman, M.; Lewis, C.; Euhus, D. M.; Bornmann, W. G.; Buchsbaum, D. J.; Spitz, D. R.; Gao, J.; Boothman, D. A. Catalase abrogates beta-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Mol. Cancer Ther. 2013, 12, 2110-20 10.1158/1535-7163.MCT-12-0962
61. Gerber, D.; Arriaga, Y.; Beg, M. S.; Dowell, J. E.; Schiller, J. H.; Frankel, A. E.; Leff, R.; Meek, C.; Bolluyt, J.; Fatunde, O.; Martinez, R. T.; Vo, P.; Fattah, F.; Sarode, V.; Zhou, Y.; Xie, Y.; McLeod, M.; Schwartz, B.; Boothman, D. A. Phase I Correlative Studies of ARQ761, a Beta-Lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis Eur. J. Cancer 2014, 50, 84-85 10.1016/S0959-8049(14)70379-X
62. Rinehart, K. L.; Renfroe, H. B. The Structure of Nybomycin J. Am. Chem. Soc. 1961, 83, 3729-3731 10.1021/ja01478a049
63. Li, S.; Tian, X.; Niu, S.; Zhang, W.; Chen, Y.; Zhang, H.; Yang, X.; Li, W.; Zhang, S.; Ju, J.; Zhang, C. Pseudonocardians A-C, new diazaanthraquinone derivatives from a deap-sea actinomycete Pseudonocardia sp. SCSIO 01299 Mar. Drugs 2011, 9, 1428-39 10.3390/md9081428
64. Tian, X. P.; Long, L. J.; Li, S. M.; Zhang, J.; Xu, Y.; He, J.; Li, J.; Wang, F. Z.; Li, W. J.; Zhang, C. S.; Zhang, S. Pseudonocardia antitumoralis sp. nov., a deoxynyboquinone-producing actinomycete isolated from a deep-sea sediment Int. J. Syst. Evol. Microbiol. 2013, 63, 893-9 10.1099/ijs.0.037135-0
65. Putt, K. S. University of Illinois at Urbana-Champaign, 2006.
66. Tudor, G.; Gutierrez, P.; Aguilera-Gutierrez, A.; Sausville, E. A. Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression Biochem. Pharmacol. 2003, 65, 1061-1075 10.1016/S0006-2952(03)00013-3
67. Rinehart, K. L.; Forbis, R. M. Nybomycin. IV. Total synthesis of deoxynybomycin J. Am. Chem. Soc. 1970, 92, 6995-6996 10.1021/ja00726a061
68. Forbis, R. M.; Rinehart, K. L. Nybomycin. VII. Preparative routes to nybomycin and deoxynybomycin J. Am. Chem. Soc. 1973, 95, 5003-5013 10.1021/ja00796a037
69. Bair, J. S.; Palchaudhuri, R.; Hergenrother, P. J. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death J. Am. Chem. Soc. 2010, 132, 5469-78 10.1021/ja100610m
70. Parkinson, E. I.; Bair, J. S.; Nakamura, B. A.; Lee, H. Y.; Kuttab, H. I.; Southgate, E. H.; Lezmi, S.; Lau, G. W.; Hergenrother, P. J. Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria Nat. Commun. 2015, 6, 6947 10.1038/ncomms7947
71. Gutierrez, P. L. The metabolism of quinone-containing alkylating agents: free radical production and measurement Front. Biosci., Landmark Ed. 2000, 5, D629-38 10.2741/gutier
72. Heeres, J. T.; Hergenrother, P. J. Poly(ADP-ribose) makes a date with death Curr. Opin. Chem. Biol. 2007, 11, 644-53 10.1016/j.cbpa.2007.08.038
73. Galluzzi, L.; Vitale, I.; Abrams, J. M.; Alnemri, E. S.; Baehrecke, E. H.; Blagosklonny, M. V.; Dawson, T. M.; Dawson, V. L.; El-Deiry, W. S.; Fulda, S.; Gottlieb, E.; Green, D. R.; Hengartner, M. O.; Kepp, O.; Knight, R. A.; Kumar, S.; Lipton, S. A.; Lu, X.; Madeo, F.; Malorni, W.; Mehlen, P.; Nunez, G.; Peter, M. E.; Piacentini, M.; Rubinsztein, D. C.; Shi, Y.; Simon, H. U.; Vandenabeele, P.; White, E.; Yuan, J.; Zhivotovsky, B.; Melino, G.; Kroemer, G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 Cell Death Differ. 2012, 19, 107-20 10.1038/cdd.2011.96
74. Faig, M.; Bianchet, M. A.; Talalay, P.; Chen, S.; Winski, S.; Ross, D.; Amzel, L. M. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 3177-82 10.1073/pnas.97.7.3177
75. Bair, J. S. University of Illinois at Urbana-Champaign, 2012.